The U.S. Food and Drug Administration approved the pill for weight loss earlier this month, intensifying Lilly's competition with rival Novo Nordisk.
The trial of 2,700 patients with increased cardiovascular risk showed that Foundayo lowered the risk of heart attack, stroke ...
The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been ...
FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill - At the heart of the request is ...
The FDA loosening and rollback of the Category 2 classification is a direct unlock for Hims’ peptide expansion, including its ...
Eli Lilly just released results of a clinical trial that may ease concerns about the safety of its new weight-loss pill ...
Eli Lilly says it has the safety data it needs to shore up the recent speedy approval of its oral obesity therapy Foundayo, ...
Eli Lilly is wasting no time in pursuit of the next indication for its newly christened obesity pill Foundayo, presenting new ...
FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...
Hims & Hers (HIMS) stock jumped 13% after FDA scheduled peptide review meetings. BofA raised price target to $25 amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results